ArticleJournal of medicinal chemistry2025
Evolution of Small Molecule Inhibitors of
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Menaquinone depletion resensitises bedaquiline-resistant tuberculosis.bioRxiv : the preprint server for biology · 2026Article
- Essential redundancies fuel Mycobacterium tuberculosis adaptation to the host.PLoS pathogens · 2025Review
- Biofilm development ofMicrobiology spectrum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Pankaj SharmaDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Quan JiangDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.ORCID 0000-0002-8851-027X
Shao-Gang LiDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Elissa OckeDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Kholiswa TsotetsiDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Paridhi SukhejaDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Parul SinghDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Shraddha SuryavanshiDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Ethan MorrisonDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Srinivas ThadkapallyDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Riccardo RussoDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Suyapa Penalva-LopezHackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States.
Julianna CangialosiHackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States.
Vijeta SharmaHackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States.
Kyla JohnsonDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Jansy P SarathyHackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States.ORCID 0000-0002-1532-146X
Andrew M NelsonHackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States.
Steven ParkHackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States.
Matthew D ZimmermanHackensack Meridian Health Center for Discovery & Innovation, Nutley, New Jersey 07110, United States.
David AllandDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Pradeep KumarDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Joel S FreundlichDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.ORCID 0000-0002-3411-3455
Funding
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI PERLIN, DAVID S · 2019 to 2023
$33.9MTherapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID · 2014 to 2018
$26.9MAcquisition of the ECHO 650 liquid handler: a multi-disciplinary, multi-laboratory tool for research, innovation and educationS10OD026890 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID · 2020 to 2020
$379kNIAID NIH HHS U19 AI109713NIAID NIH HHS U19 AI142731NIH HHS S10 OD026890
Abstract
A dire need exists for novel drugs to treat
Indexed as
Antitubercular AgentsMicrobial Sensitivity TestsMycobacterium tuberculosisVitamin K 2AnimalsMiceMicrosomes, LiverSmall Molecule LibrariesStructure-Activity RelationshipTuberculosisAntitubercular AgentsSmall Molecule LibrariesVitamin K 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.